日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nanobody Nb07 mitigates sepsis by blocking the PFKM-p53-PD-1 axis to enhance macrophage phagocytosis.

Nanobody Nb07 通过阻断 PFKM-p53-PD-1 轴来增强巨噬细胞的吞噬作用,从而减轻脓毒症。

Ji Binbin, Guo Hui, Xing Rong, Sun Miaomiao, Cheng Yu, Yao Chen, Zhu Hanyong, Wang Xuerong, Jiang Ruihan, Chen Xin, Liu Zimeng, Wang Suyan, Xu Fei, Zhang Fangyu, Dong Fuxing, Pan Xiucheng, Yang Jing, Pan Yuchen

HBV core protein enhances WDR46 stabilization to upregulate NUSAP1 and promote HCC progression.

HBV核心蛋白增强WDR46的稳定性,从而上调NUSAP1并促进HCC进展

Kong Fanyun, Bao Ensi, Zhong Yujie, Wang Yuxin, Liu Ruyu, Zhang Huanyang, Yang Lu, Jiang Rong, Liu Xuanke, Li Chen, Liu Xiangye, Pan Xiucheng, Zheng Kuiyang, You Hongjuan, Tang Renxian

Sintilimab plus a bevacizumab biosimilar (IBI305) in advanced HCC with Child-Pugh A/B liver function: a real-world multicenter retrospective study

信迪利单抗联合贝伐单抗生物类似药(IBI305)治疗Child-Pugh A/B级肝功能晚期肝细胞癌:一项真实世界多中心回顾性研究

Zhang, Yuanxu; Miao, Youhan; Sun, Wei; Yu, Yixing; Wang, Jinjing; Xiao, Shuang; Lu, Shengwei; Wang, Xia; Li, Yang; Pan, Xiucheng; Zhao, Weifeng

The ratio of GGT to PLT indices is a predictive factor for the progression of liver fibrosis in NA-treated chronic hepatitis B patients with advanced fibrosis plus PEG-IFN α-2a therapy: a case-control study

GGT/PLT比值是接受核苷(酸)类似物(NA)治疗的伴有晚期肝纤维化的慢性乙型肝炎患者加PEG-IFN α-2a治疗后肝纤维化进展的预测因子:一项病例对照研究

Li, Ling; Li, Huili; Zhao, Yiru; Shi, Lisha; Suwanbai, Mireyi; Ren, Liying; Li, Guojun; Pan, Xiucheng

Impact of nonalcoholic fatty liver disease on the functional cure of nucleos(t)ide analogues-treated chronic hepatitis B patients add-on pegylated interferon therapy: a retrospective study

非酒精性脂肪肝对接受核苷(酸)类似物治疗的慢性乙型肝炎患者加用聚乙二醇干扰素治疗后功能性治愈的影响:一项回顾性研究

Li, Huili; Li, Ling; Zhao, Yiru; Yang, Guangde; Wang, Xia; Fu, Juanjuan; Li, Li; Pan, Xiucheng

Cell binding tropism of rat hepatitis E virus is a pivotal determinant of its zoonotic transmission to humans

鼠戊型肝炎病毒的细胞结合嗜性是其人畜共患传播的关键决定因素。

Guo, Hongbo; Xu, Jiaqi; Situ, Jianwen; Li, Chunyang; Wang, Xia; Hou, Yao; Yang, Guangde; Wang, Lingli; Ying, Dong; Li, Zheng; Wang, Zijie; Su, Jia; Ding, Yibo; Zeng, Dou; Zhang, Jikai; Ding, Xiaohui; Wu, Shusheng; Miao, Weiwei; Tang, Renxian; Lu, Yihan; Kong, Huihui; Zhou, Peng; Zheng, Zizheng; Zheng, Kuiyang; Pan, Xiucheng; Sridhar, Siddharth; Wang, Wenshi

Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors

肝损伤及其对接受经动脉化疗栓塞联合酪氨酸激酶抑制剂和免疫检查点抑制剂治疗的乙型肝炎病毒相关肝细胞癌患者预后的影响

Shen, Jiaming; Wang, Xia; Yang, Guangde; Li, Li; Fu, Juanjuan; Xu, Wei; Zhang, Qingqiao; Pan, Xiucheng

The Impact of Proton Pump Inhibitors on the Efficacy of Immune Checkpoint Inhibitor Combinations in Patients with HBV-Associated Advanced Hepatocellular Carcinoma

质子泵抑制剂对乙型肝炎病毒相关晚期肝细胞癌患者免疫检查点抑制剂联合治疗疗效的影响

Wang, Ningning; Xu, Yuanyuan; Yang, Guangde; Chen, He; Wang, Xia; Fu, Juanjuan; Li, Li; Pan, Xiucheng

Insights into the impact of hepatitis B virus on hepatic stellate cell activation

深入探究乙型肝炎病毒对肝星状细胞活化的影响

You, Hongjuan; Wang, Xing; Ma, Lihong; Zhang, Fulong; Zhang, Huanyang; Wang, Yuxin; Pan, Xiucheng; Zheng, Kuiyang; Kong, Fanyun; Tang, Renxian

HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors

乙型肝炎病毒再激活及其对接受经动脉化疗栓塞联合酪氨酸激酶抑制剂和免疫检查点抑制剂治疗的乙型肝炎相关肝癌患者生存率的影响

Shen, Jiaming; Wang, Xia; Wang, Ningning; Wen, Shifei; Yang, Guangde; Li, Li; Fu, Juanjuan; Pan, Xiucheng